Sativa’s earlier business model was aimed to take advantage of well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector in North America. The Company invested in two Canadian companies; Rapid Dose Therapeutics, and Veritas Pharma Inc. These companies have enhanced Sativa’s market position by aiding valuable market research, particularly in the area of seed selection and dosing efficacy.
Following regulatory changes, Sativa has adapted its business strategy to incorporate the UK and European markets. The Company is capitalising on “Seed to Consumer” strategy, focusing on the smart-sourcing of the raw material, advanced extraction, manufacture, testing, distribution and research & development of medicinal cannabis and Cannabinoid products.
Two UK businesses, George Botanicals and PhytoVista Laboratories, are already fully operational, since being set up in June and July 2018, respectively. Other important future revenue streams, including the retail business Goodbody & Blunt, are at various points of development from early stage to commercial launch. The Company is excited to open the first of three pilot stores in Bath, after which Sativa intends roll-out a national franchise.
Sativa GmbH, the 60% owned German subsidiary, is applying for an import and wholesale licence to distribute the Group’s CBD and Medicinal Cannabis products within the German market. Alongside the operating businesses, we have established The Sativa Foundation, which will award research grants to academic and other institutions to further research into the efficacy of Medicinal Cannabis. The first grant was awarded to Kings College London in April 2019.
Rapid Dose Therapeutics, RDT, is a Canadian bio-technology company which provides disruptive proprietary drug delivery technologies designed to improve patient outcomes.
Formed because of a recognized need to move drug delivery to a new level. RDT provides product innovation, production, and consultation to the pharmaceutical and healthcare manufacturing industry.
Proprietary oral fast-dissolving drug delivery system, QuickStrip™, rapidly releases an expansive list of pharmaceuticals, emulsified oils, and a host of over-the-counter medicines. This permits API’s to enter the blood stream through a rapid dose pathway without being degraded or modified by first pass metabolism in the liver.
How rapid is a Rapid Dose Therapeutic? Studies show the QuickStrip™ technology delivery mimics blood concentrations over time to intravenous injection.
Sublingual and transmucosal transport of active molecules result from the rapid dissolution of QuickStrip™ combined with the proprietary technology.
Veritas Pharma Inc. is an emerging global pharmaceutical company based out of Vancouver, Canada that’s investing in the discovery, product development and commercialization of effective, patented cannabis therapies that target disease conditions in the areas of chronic pain, senior long-term care and palliative care.
Through its subsidiary company, Cannevert Therapeutics Ltd., it aims to obtain comprehensive scientific evidence, for health care professionals and patients so that they can utilize these strains with confidence of a reliable therapeutic effect. Cannevert is made up of a strong management team, bringing together veteran academic pharmacologists, anesthetists and chemists, and each contributing to the critical need for preclinical and clinical data to support medical cannabis claims. It also has a Health Canada Dealer License, enabling it to import cannabis products from any part of the World as well as produce extracts for sell to Canadian licensed producers and aboard through an export permit. This allows Veritas to establish and promote globally the Cannevert brand of cannabis-based medicines.
Veritas’ investment in partnerships such as 3 Carbon Extractions Inc. and BioCan Technologies Inc., will enable it to codevelop cannabis extracts and delivery devices using not only Cannevert’s proprietary cannabis strains for upcoming clinical trials but also create newer strains that can address more unmet medical needs.
Veritas Pharma is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
Henry Lees-Buckley – Chief Executive Officer of Sativa Group PLC, is a seasoned corporate executive, with extensive experience of leading companies in the public markets. Henry was previously CEO of Uni-Select [TSX:UNS], a Canadian TSX quoted company, with operations in the UK, Canada and the USA. Prior to that, he was a senior global executive and officer in the USA and Canada for W.W. Grainger, a US$15 billion Fortune 500 company. Henry is currently a non-Executive Director of NASDAQ-quoted BMC (Building Materials Corp) [NASDAQ:BMCH] which has sales of US$3.8 billion and a market capitalisation of US$1.6 billion. Henry holds an MBA from Queens University, Kingston, Ontario and has held numerous executive level positions both in North America and also the United Kingdom
Founder and Deputy Chairman
Geremy Thomas, is a serial entrepreneur with a successful track record in the telecommunication, e-learning and consumer finance industries. Geremy co-founded The Carphone Group Plc in the late 1980’s and grew the business to exceed 10% market share before selling to Cable & Wireless for £16m. This was followed by the creation and listing of PNC Telecom Plc, a telecoms business that at its peak was valued at over £200m. In 2001 Geremy co-founded TMTI Ltd. TMTI is a highly profitable technical support business which works with the major brands in enhancing the customer experience. George Banco ltd, a consumer Finance business started by Thomas in 2013, was recently sold to Non Standard Finance Plc for £53m. Other business interests include Carbon Managers ltd an environmental services consultancy company.
Joseph is a qualified Chartered Accountant with significant management consulting experience. Before joining Sativa, Joseph was a Director of Consulting at Kantar Consulting, part of WPP plc (“WPP”) which advises Retail, Sales and Shopper clients on enhancing their commercial capability and the commercial competency of their staff. Prior to this, Joseph was Chief Financial Officer and a senior board member at WPP’s Kantar Futures, which advises its clients on enhancing profit through change and shaping strategy. Here, Joseph was accountable for financial performance, managing a global finance team. From 2012 – 2015 Joseph was Global Commercial Director of WPP’s Kantar subsidiary Taylor Nelson Sofres, a $1.8 billion turnover marketing agency.
Before joining WPP, Joseph was an Audit Senior at Mazars LLP, where he qualified as an Accountant with the Institute of Chartered Accountants in England and Wales (ICAEW), being made a Fellow in 2018. He gained a Geophysics BSc (Hons) 2:1 from Southampton University.
As at the date of this announcement, Joseph has been granted 3,350,000 share options in the Company at 1.5p
Angus is an adviser and capital markets professional with nearly 25 years’ experience in global banking with specific expertise in strategic and equity advisory, M&A and ECM. He has held, inter alia, managing director and management roles covering advisory, equity advisory and ECM at a number of organisations, including head of Mid-Market Advisory and Broking at Credit Suisse and head of UK ECM Dresdner Kleinwort. He has a long track record of advising companies and high profile individuals in the UK, USA and Europe.
He is currently a Senior Advisor at Zeus Capital, the independent investment bank, and is also Chairman of North Berwick SA, a business that consolidates portfolios of company-owned life insurance, and of the advisory board of Luxon Payments Ltd, a company using block chain distributed ledger technology to create a global electronic wallet.
Prior to his career in finance Angus was an Army Officer. Angus has a BA (Hons) in Politics and International Relations from the University of Reading.
Mark Blower, non-Executive Director, is an experienced finance professional, having spent the last 20 years actively overseeing the financial performance of over 70 UK SME’s, with a particular focus on raising debt and private equity. He began his career in 1996 at the Investment Banking division of a large UK bank, before joining NM Rothschild in 2000. He then ran a highly successful leveraged debt team for another UK lending institution for five years before starting his Private Equity career in 2010. During his career to-date he has held a number of board positions, across a variety of sectors.
Jonathan joins as non-Executive Chairman. Jonathan is an experienced, City-based corporate financier, who began his City career after graduating from Cambridge University with a M.A. in Economics. He was Chairman of Ideagen plc on its admission to the AIM market in July 2012 until April 2018 and remains a non-Executive Director. Following eight years in Citibank London’s corporate banking division, providing debt finance for growth and acquisition purposes, he moved to Citicorp’s London investment bank (CIBL) where, as a Director in the Corporate Finance Department, he worked on both UK and cross-border transactions.
Cenkos Securities PLC
RSM UK Audit LLP
The Blue Building, Stubbs Lane, Beckington, Somerset BA11 6TE
E-mail: [email protected]
Cenkos Securities PLC
RSM UK Audit LLP